ResMed Can't Yet Count on New Demand Drivers -- Market Talk

Dow Jones

Feb 03, 2025

0022 GMT - The idea that fitness wearables or weight-loss drugs could create a step-change in demand for ResMed is too underdeveloped to incorporate into earnings forecasts, Wilsons analyst Shane Storey says. Cutting his recommendation on the breath-tech provider to market weight from overweight, Storey concedes that the growing use of GLP-1 drugs is a potential tailwind to the sleep industry, but thinks its impact can't yet be predicted. He writes in a note that ResMed's manufacturing and procurement initiatives, and scale benefits, will materialize in fiscal 2026 and fiscal 2027. Wilsons lifts its target price by 1.5% to A$42.82. Shares are down 3.2% at A$38.90. (stuart.condie@wsj.com)

(END) Dow Jones Newswires

February 02, 2025 19:22 ET (00:22 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"Tiger Brokers,U.S. stock trading,Hong Kong stock trading,trading U.S. stocks,stock information,stock prices,U.S. stock quotes,U.S. stock trading,Hong Kong stock trading,IPO trading,buying U.S. stocks,global investment","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2508578011"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2508578011\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2508578011?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-03 08:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2508578011","market":"fut","top_or_hot":-1,"title":"ResMed Can't Yet Count on New Demand Drivers -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0022 GMT - The idea that fitness wearables or weight-loss drugs could create a step-change in demand for ResMed is too underdeveloped to incorporate into earnings forecasts, Wilsons analyst Shane Storey says. Cutting his recommendation on the breath-tech provider to market weight from overweight, Storey concedes that the growing use of GLP-1 drugs is a potential tailwind to the sleep industry, but thinks its impact can't yet be predicted. He writes in a note that ResMed's manufacturing and procurement initiatives, and scale benefits, will materialize in fiscal 2026 and fiscal 2027. Wilsons lifts its target price by 1.5% to A$42.82. Shares are down 3.2% at A$38.90. (stuart.condie@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 02, 2025 19:22 ET (00:22 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ResMed Can't Yet Count on New Demand Drivers -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nResMed Can't Yet Count on New Demand Drivers -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-02-03 08:22</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0022 GMT - The idea that fitness wearables or weight-loss drugs could create a step-change in demand for ResMed is too underdeveloped to incorporate into earnings forecasts, Wilsons analyst Shane Storey says. Cutting his recommendation on the breath-tech provider to market weight from overweight, Storey concedes that the growing use of GLP-1 drugs is a potential tailwind to the sleep industry, but thinks its impact can't yet be predicted. He writes in a note that ResMed's manufacturing and procurement initiatives, and scale benefits, will materialize in fiscal 2026 and fiscal 2027. Wilsons lifts its target price by 1.5% to A$42.82. Shares are down 3.2% at A$38.90. (stuart.condie@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 02, 2025 19:22 ET (00:22 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4548","symbol_name":"巴美列捷福持仓","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2508578011","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2508578011","pubTimestamp":1738542120,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0022 GMT - The idea that fitness wearables or weight-loss drugs could create a step-change in demand for ResMed is too underdeveloped to incorporate into earnings forecasts, Wilsons analyst Shane Storey says. Cutting his recommendation on the breath-tech provider to market weight from overweight, Storey concedes that the growing use of GLP-1 drugs is a potential tailwind to the sleep industry, but thinks its impact can't yet be predicted. He writes in a note that ResMed's manufacturing and procurement initiatives, and scale benefits, will materialize in fiscal 2026 and fiscal 2027. Wilsons lifts its target price by 1.5% to A$42.82. Shares are down 3.2% at A$38.90. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4548":"巴美列捷福持仓","BK4567":"ESG概念","RMD":"瑞思迈","BK4082":"医疗保健设备","BK4504":"桥水持仓","RMD.AU":"Resmed DRC","LU2177674079.SGD":"Fidelity Asia Pacific Opportunities A-ACC-SGD (hedged)","BK7501":"新冠治疗股","LU2008162690.USD":"FIDELITY FUNDS - ASIA PACIFIC OPPORTUNITIES \"A\" (USD) ACC","BK4588":"碎股","BK7007":"医疗保健设备","BK4585":"ETF&股票定投概念"},"translate_title":"瑞思迈还不能指望新的需求驱动因素——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RMD.AU":0.9,"RMD":1},"content_text":"0022 GMT - The idea that fitness wearables or weight-loss drugs could create a step-change in demand for ResMed is too underdeveloped to incorporate into earnings forecasts, Wilsons analyst Shane Storey says. Cutting his recommendation on the breath-tech provider to market weight from overweight, Storey concedes that the growing use of GLP-1 drugs is a potential tailwind to the sleep industry, but thinks its impact can't yet be predicted. He writes in a note that ResMed's manufacturing and procurement initiatives, and scale benefits, will materialize in fiscal 2026 and fiscal 2027. Wilsons lifts its target price by 1.5% to A$42.82. Shares are down 3.2% at A$38.90. (stuart.condie@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 02, 2025 19:22 ET (00:22 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}